Wellbutrin: adverse event reports filed with FDA

13,341

reports as suspect product

0.1% of all reports · about 593 a year

224

reports, 12 months to June 2026

178 in the 12 months before

30.3%

marked serious by the reporter

57.6% across the class

2.4%

record death among outcomes, as reported

319 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Wellbutrin reports recording the termmedian drug in aminoketone

1. Drug ineffectivethe medicine did not work as expected12.1%1,617
2. Insomniadifficulty sleeping7.3%979
3. Nauseafeeling sick6.7%898
4. Headachehead pain6.6%874
5. Anxietyanxiety6.5%862
6. Dizzinesslight-headedness or unsteadiness5.9%782
7. Depressionlow mood5.6%753
8. Rashskin rash4.3%567
9. Tremorshaking3.9%524
10. Fatiguetiredness3.7%498
11. Feeling abnormalfeeling odd or not right3.5%470
12. Tinnitusringing in the ears3.4%460
13. Agitationrestlessness3.3%445
14. Convulsion2.8%379
15. Urticariahives2.6%345
16. Alopeciahair loss2.5%329
17. Weight increasedweight gain2.5%327
18. Suicidal ideationthoughts of suicide2.4%326
19. Irritabilityirritability2.2%298
20. Pruritusitching2.2%295
21. Dry mouthdry mouth2.2%291
22. Off label useused for a purpose or in a way not on the label2.1%276
23. Hyperhidrosisexcessive sweating2.1%274
24. Pharmaceutical product complaint2%265
25. Overdosea dose above the recommended amount1.9%260
26. Hypertensionhigh blood pressure1.9%258
27. Weight decreasedweight loss1.9%258
28. Somnolencedrowsiness1.9%254
29. Constipationconstipation1.8%246
30. Malaisegeneral feeling of being unwell1.8%241

Top 30 of 1,203 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 6 drugs in the aminoketone class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 70,951 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 71.1% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 13,341 reports.

Drugs most often listed in the same reports

Other products listed in reports where Wellbutrin is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the aminoketone class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Wellbutrin as a suspect or interacting product; reports listing it only as a concomitant medication (11,568) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.